Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent
dc.contributor.author | Thangamani, Shankar | en |
dc.contributor.author | Mohammad, Haroon | en |
dc.contributor.author | Abushahba, Mostafa FN N. | en |
dc.contributor.author | Hamed, Maha I. | en |
dc.contributor.author | Sobreira, Tiago JP P. | en |
dc.contributor.author | Hedrick, Victoria E. | en |
dc.contributor.author | Paul, Lake N. | en |
dc.contributor.author | Seleem, Mohamed N. | en |
dc.date.accessioned | 2020-09-21T16:15:43Z | en |
dc.date.available | 2020-09-21T16:15:43Z | en |
dc.date.issued | 2015-11-10 | en |
dc.date.updated | 2020-09-21T16:15:41Z | en |
dc.description.abstract | The rapid rise of bacterial resistance to traditional antibiotics combined with the decline in discovery of novel antibacterial agents has created a global public health crisis. Repurposing existing drugs presents an alternative strategy to potentially expedite the discovery of new antimicrobial drugs. The present study demonstrates that simvastatin, an antihyperlipidemic drug exhibited broad-spectrum antibacterial activity against important Gram-positive (including methicillin-resistant Staphylococcus aureus (MRSA)) and Gram-negative pathogens (once the barrier imposed by the outer membrane was permeabilized). Proteomics and macromolecular synthesis analyses revealed that simvastatin inhibits multiple biosynthetic pathways and cellular processes in bacteria, including selective interference of bacterial protein synthesis. This property appears to assist in simvastatin's ability to suppress production of key MRSA toxins (α-hemolysin and Panton-Valentine leucocidin) that impair healing of infected skin wounds. A murine MRSA skin infection experiment confirmed that simvastatin significantly reduces the bacterial burden and inflammatory cytokines in the infected wounds. Additionally, simvastatin exhibits excellent anti-biofilm activity against established staphylococcal biofilms and demonstrates the ability to be combined with topical antimicrobials currently used to treat MRSA skin infections. Collectively the present study lays the foundation for further investigation of repurposing simvastatin as a topical antibacterial agent to treat skin infections. | en |
dc.description.version | Published version | en |
dc.format.extent | 13 page(s) | en |
dc.format.medium | Electronic | en |
dc.format.mimetype | application/pdf | en |
dc.identifier | ARTN 16407 (Article number) | en |
dc.identifier.doi | https://doi.org/10.1038/srep16407 | en |
dc.identifier.eissn | 2045-2322 | en |
dc.identifier.issn | 2045-2322 | en |
dc.identifier.issue | 1 | en |
dc.identifier.orcid | Seleem, Mohamed [0000-0003-0939-0458] | en |
dc.identifier.other | srep16407 (PII) | en |
dc.identifier.pmid | 26553420 (pubmed) | en |
dc.identifier.uri | http://hdl.handle.net/10919/100038 | en |
dc.identifier.volume | 5 | en |
dc.language.iso | en | en |
dc.publisher | Nature Publishing Group | en |
dc.rights | Creative Commons Attribution 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | RESISTANT STAPHYLOCOCCUS-AUREUS | en |
dc.subject | COA REDUCTASE INHIBITORS | en |
dc.subject | COENZYME-A REDUCTASE | en |
dc.subject | MACROMOLECULAR-SYNTHESIS | en |
dc.subject | ANTIMICROBIAL PEPTIDES | en |
dc.subject | STATINS | en |
dc.subject | ANTIBIOTICS | en |
dc.subject | EXPRESSION | en |
dc.subject | VIRULENCE | en |
dc.subject | THERAPY | en |
dc.subject.mesh | Animals | en |
dc.subject.mesh | Mice | en |
dc.subject.mesh | Biofilms | en |
dc.subject.mesh | Gram-Negative Bacteria | en |
dc.subject.mesh | Staphylococcus | en |
dc.subject.mesh | Staphylococcal Skin Infections | en |
dc.subject.mesh | Disease Models, Animal | en |
dc.subject.mesh | Simvastatin | en |
dc.subject.mesh | Inflammation Mediators | en |
dc.subject.mesh | Cytokines | en |
dc.subject.mesh | Hydroxymethylglutaryl-CoA Reductase Inhibitors | en |
dc.subject.mesh | Anti-Bacterial Agents | en |
dc.subject.mesh | Microbial Sensitivity Tests | en |
dc.subject.mesh | Administration, Topical | en |
dc.subject.mesh | Drug Synergism | en |
dc.subject.mesh | Female | en |
dc.subject.mesh | Metabolic Networks and Pathways | en |
dc.subject.mesh | Methicillin-Resistant Staphylococcus aureus | en |
dc.subject.mesh | Hypolipidemic Agents | en |
dc.subject.mesh | Proteolysis | en |
dc.title | Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent | en |
dc.title.serial | Scientific Reports | en |
dc.type | Article - Refereed | en |
dc.type.dcmitype | Text | en |
dc.type.other | Article | en |
dc.type.other | Journal | en |
dcterms.dateAccepted | 2015-10-13 | en |
pubs.organisational-group | /Virginia Tech/Veterinary Medicine | en |
pubs.organisational-group | /Virginia Tech/Faculty of Health Sciences | en |
pubs.organisational-group | /Virginia Tech/All T&R Faculty | en |
pubs.organisational-group | /Virginia Tech/Veterinary Medicine/Biomedical Sciences and Pathobiology | en |
pubs.organisational-group | /Virginia Tech/Veterinary Medicine/CVM T&R Faculty | en |
pubs.organisational-group | /Virginia Tech | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent.pdf
- Size:
- 1.11 MB
- Format:
- Adobe Portable Document Format